One batch has 11.4 million units of Naproxen tablets out of which 0.9 million units that were released into the market were recalled
The drug has been granted permission by DCGI for emergency use as an adjunct therapy for Covid-19
Acetaminophen extended-release tablets 650 mg is bioequivalent of the reference listed drug Tylenol
India is dependent upon China and other countries for a lot of Key Starting Materials (KSM) for their bulk drug needs.
The company has an outlay of Rs 120-140 crore as R & D expense for FY 22
The company posted net profit of Rs.111.44 crores for the period ended June 30, 2020.
The US FDA has closed the observations pertaining to this audit with an Establishment Inspection Report on the 20th of July 2021
In an exclusive interview with Rahul Koul of Indian Chemical News, Priyanka Chigurupati, Executive Director, Granules Pharmaceuticals Inc. USA shared details about the company's performance, R&D initiatives, Capex plan, CSR, and future outlook. Excerpts of the interview:
The company will provide one crore tablets every week, starting from 12th May 2021, aggregating to 16 crore tablets worth Rs. 8 crores over the next 4 months
ranules now has a total of 38 ANDA approvals from US FDA.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
